Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain.
Conclusions Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs.
PMID: 31686550 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Antibiotic Therapy | Avelox | Ceftriaxone | Economics | Health Management | Levaquin | Moxifloxacin | Pneumonia | Rocephin | Spain Health